Innovative Minimally Invasive Approach for Neurological Conditions Has Been Used in 1,000 Patient Procedures
PLYMOUTH, Minn., Oct. 18, 2016 /PRNewswire/ -- Monteris Medical today announced that leading surgeons at 40 sites across the U.S. and Canada have used the company's NeuroBlate® System, a minimally invasive robotic laser thermotherapy tool, in more than 1,000 patient procedures.
"NeuroBlate is a significant advance in neurosurgery, offering the potential to improve clinical outcomes for patients," said Eric C. Leuthardt, M.D., Professor of Neurological Surgery at Barnes-Jewish Hospital and Director of the Center for Innovation in Neuroscience and Technology, and the Brain Laser Center at Washington University School of Medicine. "And because NeuroBlate is a minimally invasive tool, we are seeing reductions in pain and shorter recovery times compared with traditional open surgery."
Read More: http://www.prnewswire.com/news-releases/monteris-medical-reaches-milestone-for-neuroblate-system-300346443.html
Via: PR Newswire
Study shows seniors at risk for diabetes and heart disease lose weight, reduce healthcare costs with Omada's program
The digital behavioral health coaching program from Omada Health has been shown to reduce overweight and obese seniors' risk of developing type 2 diabetes and heart disease by helping them lose weight and adopt healthier behaviors, according to a new study.
Peer-Reviewed Study Demonstrates Omada Program Helps Seniors Reduce Risk of Type 2 Diabetes and Heart Disease
Via: Omada Health
Company’s fifth peer-reviewed publication shows seniors engage with the Omada Program and lose weight; model estimates savings in less than two years
OncoMed Presents Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 Congress
COPENHAGEN, Denmark and REDWOOD CITY, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) today announced the presentation of interim clinical data from its ongoing Phase 1b trials of ipafricept (FZD8-Fc, OMP-54F28) and vantictumab (anti-Fzd, OMP-18R5) at the European Society of Medical Oncology (ESMO) 2016 Congress.
In-center self-care hemodialysisis associated with better outcomes than traditional in-center hemodialysis.
While Omada Health’s Prevent program is designed for individuals with prediabetes, it can be adapted to patients who already have diabetes, because the program is built on behavior change and modification, explained Mike Payne, MBA, MSci, chief healthcare development officer at Omada Health.
Silk Road Medical Announces New Medicare Coverage Option for TransCarotid Artery Revascularization (TCAR) Procedures
Via: PR Newswire
Medicare to Cover Procedures within the TCAR Surveillance Project Sponsored by the Society for Vascular Surgery
NEW CAROTID ARTERY STENT PROCEDURE TO BE EVALUATED BY
Edward R Jones, MD, MBA, FACP LaRhondd James, RN Sophid Rosen, PhD
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
Results Expected in the First Half of 2017